Abstract
A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions.
MeSH terms
-
Adrenal Glands / drug effects
-
Adrenocorticotropic Hormone / blood
-
Aged
-
Androgen Antagonists / administration & dosage*
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Chlormadinone Acetate / therapeutic use
-
Corticotropin-Releasing Hormone / pharmacology
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / physiopathology
-
Humans
-
Hypothalamo-Hypophyseal System / drug effects*
-
Hypothalamo-Hypophyseal System / pathology
-
Male
-
Pituitary-Adrenal System / drug effects*
-
Pituitary-Adrenal System / pathology
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / complications
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / physiopathology
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Antineoplastic Agents
-
Chlormadinone Acetate
-
Adrenocorticotropic Hormone
-
Corticotropin-Releasing Hormone